...
首页> 外文期刊>Clinical epigenetics. >Global histone modification profiling reveals the epigenomic dynamics during malignant transformation in a four-stage breast cancer model
【24h】

Global histone modification profiling reveals the epigenomic dynamics during malignant transformation in a four-stage breast cancer model

机译:全局组蛋白修饰图谱揭示了四阶段乳腺癌模型恶性转化过程中的表观基因组动力学

获取原文
           

摘要

BackgroundEpigenetic regulation has emerged to be the critical steps for tumorigenesis and metastasis. Multiple histone methyltransferase and demethylase have been implicated as tumor suppressors or oncogenes recently. But the key epigenomic events in cancer cell transformation still remain poorly understood. MethodsA breast cancer transformation model was established via stably expressing three oncogenes in primary breast epithelial cells. Chromatin immunoprecipitation followed by the next-generation sequencing of histone methylations was performed to determine epigenetic events during transformation. Western blot, quantitative RT-PCR, and immunostaining were used to determine gene expression in cells and tissues. ResultsHistones H3K9me2 and me3, two repressive marks of transcription, decrease in in vitro breast cancer cell model and in vivo clinical tissues. A survey of enzymes related with H3K9 methylation indicated that KDM3A/JMJD1A, a demethylase for H3K9me1 and me2, gradually increases during cancer transformation and is elevated in patient tissues. KDM3A/JMJD1A deficiency impairs the growth of tumors in nude mice and transformed cell lines. Genome-wide ChIP-seq analysis reveals that the boundaries of decreased H3K9me2 large organized chromatin K9 modifications (LOCKs) are enriched with cancer-related genes, such as MYC and PAX3. Further studies show that KDM3A/JMJD1A directly binds to these oncogenes and regulates their transcription by removing H3K9me2 mark. ConclusionsOur study demonstrates reduction of histones H3K9 me2 and me3, and elevation of KDM3A/JMJD1A as important events for breast cancer, and illustrates the dynamic epigenomic mechanisms during breast cancer transformation.
机译:背景技术表观遗传调节已成为肿瘤发生和转移的关键步骤。最近,多种组蛋白甲基转移酶和脱甲基酶被认为是肿瘤抑制物或癌基因。但是,癌细胞转化中关键的表观基因组事件仍然知之甚少。方法通过在原发性乳腺上皮细胞中稳定表达三种癌基因,建立乳腺癌转化模型。进行染色质免疫沉淀,然后进行下一代组蛋白甲基化测序,以确定转化过程中的表观遗传事件。 Western印迹,定量RT-PCR和免疫染色被用于确定细胞和组织中的基因表达。结果组蛋白H3K9me2和me3是转录的两个阻遏标记,在体外乳腺癌细胞模型和体内临床组织中均降低。一项与H3K9甲基化相关的酶研究表明,KDM3A / JMJD1A(H3K9me1和me2的脱甲基酶)在癌症转化过程中逐渐增加,并在患者组织中升高。 KDM3A / JMJD1A缺乏会损害裸鼠和转化细胞系中肿瘤的生长。全基因组ChIP-seq分析显示,减少的H3K9me2大型有组织的染色质K9修饰(LOCKs)的边界富含与癌相关的基因,例如MYC和PAX3。进一步的研究表明,KDM3A / JMJD1A直接与这些癌基因结合,并通过去除H3K9me2标记来调节其转录。结论我们的研究表明组蛋白H3K9 me2和me3的减少以及KDM3A / JMJD1A升高是乳腺癌的重要事件,并阐明了乳腺癌转化过程中的动态表观基因组机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号